A new drug summary about an investigational HIV drug called 10-1074 is available on Clinicalinfo.

• 10-1074 is being studied to treat and prevent HIV infection and is currently in Phase 2 development as an HIV therapeutic. It is a broadly neutralizing antibody (bNAb), a powerful type of antibody that can work against many HIV strains. bNAbs can block HIV from entering healthy cells and activate other immune cells to help destroy infected cells. Long-acting forms of 10-1074 are also under study. For more information about 10-1074, see the patient and health professional drug summaries.

To learn more about investigational HIV medicines, check out the HIVinfo What is an Investigational HIV Drug? fact sheet